Efficacy, safety and pharmacokinetics of artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in HIV infected Malawian children on antiretroviral treatment

Start and End dates: 2020 to 2023

Source of Funding: European and Developing Countries Clinical Trials Partnership (EDCTP) ($167,000

This is a prospective, non-randomised intervention trial assessing the efficacy, safety and pharmacokinetics of artemether lumenfantirne in HIV infected versus HIV non-infected children in Malawi. We shall recruit 280 children under 16 years of age who have malaria parasitaemia and require treatment, and we shall follow them up for 28 days to assess their treatment outcome.